Last Updated: November 16, 2026

Drug Sales Trends for FOCALIN XR

« Back to Dashboard


Payment Methods and Pharmacy Types for FOCALIN XR (2022)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $76,551,872
INSIDE HMO/CLINIC/HOSPITAL $22,920,213
[disabled in preview] $428,968,247
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 168,646
INSIDE HMO/CLINIC/HOSPITAL 88,169
[disabled in preview] 806,510
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $224,700,632
PRIVATE INSURANCE $292,488,867
[disabled in preview] $11,250,833
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for FOCALIN XR
Drug Units Sold Trends for FOCALIN XR

Annual Sales Revenues and Units Sold for FOCALIN XR

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
FOCALIN XR ⤷  Start Trial ⤷  Start Trial 2022
FOCALIN XR ⤷  Start Trial ⤷  Start Trial 2021
FOCALIN XR ⤷  Start Trial ⤷  Start Trial 2020
FOCALIN XR ⤷  Start Trial ⤷  Start Trial 2019
FOCALIN XR ⤷  Start Trial ⤷  Start Trial 2018
FOCALIN XR ⤷  Start Trial ⤷  Start Trial 2017
>Drug Name >Revenues (USD) >Units >Year

Focalin XR Market Analysis, Sales Forecast, Patent Status, and Generic Competition

Last updated: September 1, 2026

Focalin XR, the extended-release formulation of dexmethylphenidate hydrochloride, is a mature ADHD medicine with limited brand-sales potential and a larger generic opportunity. Its market is driven by ADHD diagnosis growth, stimulant shortages, payer substitution, and prescribing preference for long-acting methylphenidate products. Generic competition has removed most of the brand’s pricing power.

A base-case forecast estimates U.S. annual market revenue for dexmethylphenidate extended-release products at approximately $115 million in 2025, increasing to $135 million by 2029. Estimated branded Focalin XR revenue is substantially lower, at approximately $15 million to $25 million annually, while generic products capture most unit volume.

What is Focalin XR and how large is its addressable market?

Focalin XR is an extended-release capsule containing dexmethylphenidate hydrochloride, the d-enantiomer of methylphenidate. Novartis developed and commercialized the product for attention-deficit/hyperactivity disorder, or ADHD. The FDA approved Focalin XR in 2005 for patients aged six years and older at the time of initial labeling. The current prescribing information covers pediatric and adult use, subject to the labeled dosing and safety limitations. (U.S. Food and Drug Administration, 2024a)

Focalin XR uses a bimodal release profile intended to provide an initial release phase followed by a later release phase. Available strengths include 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, and 40 mg capsules. Patients may swallow the capsules or administer the contents in certain permitted ways described in the label. (U.S. Food and Drug Administration, 2024a)

U.S. ADHD market drivers

The commercial market is supported by:

  • More than 7 million U.S. children and adolescents diagnosed with ADHD in recent national survey data.
  • Expanded adult ADHD diagnosis and treatment.
  • Preference among some prescribers for once-daily stimulant formulations.
  • Switching during shortages affecting amphetamine and methylphenidate products.
  • Continued use of methylphenidate products when amphetamine products cause adverse effects or inadequate symptom control.

CDC survey data show that ADHD diagnosis and treatment remain significant across pediatric age groups. Adult treatment data are less complete, but adult ADHD prescribing has expanded over the past decade. (Centers for Disease Control and Prevention, 2024)

The addressable market is narrower than the total ADHD market because Focalin XR competes with Concerta, Ritalin LA, Aptensio XR, Jornay PM, Quillivant XR, Vyvanse, Adderall XR, Azstarys, and generic methylphenidate formulations.

How much revenue does Focalin XR generate?

Novartis does not report current Focalin XR revenue as a separate line item in its public financial statements. The brand is a mature product and is not a material contributor to the company’s consolidated revenue disclosures. Public prescription databases and commercial IQVIA data are required for a definitive current brand-sales figure.

The following estimate separates the total U.S. dexmethylphenidate extended-release market from branded Focalin XR revenue.

Year U.S. extended-release dexmethylphenidate market Estimated branded Focalin XR revenue Generic revenue Base-case growth
2024 $110 million $18 million $92 million Baseline
2025 $115 million $17 million $98 million 4.5%
2026 $120 million $17 million $103 million 4.3%
2027 $125 million $16 million $109 million 4.2%
2028 $130 million $16 million $114 million 4.0%
2029 $135 million $15 million $120 million 3.8%

These figures are a market model based on estimated prescription growth, generic price erosion, and stable-to-declining brand share. They are not company guidance.

The principal revenue opportunity is generic dexmethylphenidate extended release rather than branded Focalin XR. Generic manufacturers can compete through pharmacy substitution, lower acquisition cost, and coverage under commercial and Medicaid formularies.

What are the Focalin XR sales projections through 2029?

Base-case scenario

The base case assumes:

  • U.S. prescription volume growth of 2% to 3% annually.
  • Average net pricing growth of approximately 1%.
  • Brand share declining by roughly 1 to 2 percentage points annually.
  • No major new long-acting dexmethylphenidate entrant.
  • Periodic stimulant shortages that increase switching but do not permanently expand Focalin XR share.

Under these assumptions, total extended-release dexmethylphenidate revenue reaches about $135 million in 2029. Branded Focalin XR revenue declines because generic substitution offsets volume growth.

Upside scenario

The upside case reaches approximately $155 million in total U.S. market revenue by 2029. It requires:

  • Continued shortages of competing stimulant products.
  • Higher adult ADHD treatment rates.
  • Improved supply reliability for dexmethylphenidate products.
  • Stable prescriber preference for methylphenidate-based therapy.
  • Limited generic discounting.

Brand revenue would still remain constrained because the product has already lost substantial market exclusivity.

Downside scenario

The downside case produces approximately $90 million to $100 million in 2029 market revenue. It assumes:

  • Greater substitution to amphetamine products, Vyvanse generics, or newer stimulant formulations.
  • Persistent generic price compression.
  • Reduced stimulant prescribing caused by tighter controlled-substance monitoring.
  • Increased use of nonstimulants such as atomoxetine, viloxazine, and guanfacine.
  • Supply disruptions affecting dexmethylphenidate products.

When does Focalin XR lose exclusivity?

Focalin XR no longer has meaningful commercial exclusivity in the United States. FDA-approved generic versions of dexmethylphenidate hydrochloride extended-release capsules entered the market years after the original brand approval. FDA’s Orange Book lists the reference product and related generic approvals under the same active ingredient and dosage-form category. (U.S. Food and Drug Administration, 2024b)

The relevant commercial event was generic entry, not the expiration of a single remaining patent. Generic approval eliminated the brand’s ability to maintain premium pricing even where residual patent rights or regulatory protections existed.

Patent and regulatory position

The key protection historically associated with Focalin XR was its extended-release formulation and related product patents. The patent estate is now commercially weak because:

  1. The core product has been exposed to generic competition.
  2. Generic products have received FDA approval.
  3. Pharmacy substitution reduces the brand’s ability to preserve volume.
  4. Formulation differences can be addressed through abbreviated new drug application pathways when the FDA determines bioequivalence.

Focalin XR was approved under NDA 021278. Generic dexmethylphenidate hydrochloride extended-release capsules are approved through ANDAs referencing the brand product. (U.S. Food and Drug Administration, 2024a; U.S. Food and Drug Administration, 2024b)

A current transaction or litigation assessment should rely on the live Orange Book patent listing and court docket records. The commercial conclusion is clear: Focalin XR has no effective U.S. exclusivity barrier preventing generic substitution.

Which companies compete with Focalin XR?

Direct methylphenidate competitors

Focalin XR competes directly with:

  • Generic methylphenidate extended-release tablets and capsules.
  • Concerta and authorized or generic versions.
  • Ritalin LA.
  • Aptensio XR.
  • Jornay PM.
  • Quillivant XR.
  • Quillichew ER.
  • Cotempla XR-ODT.
  • Azstarys, which contains serdexmethylphenidate and dexmethylphenidate.

Amphetamine competitors

The major therapeutic substitutes are:

  • Adderall XR and generic mixed amphetamine salts extended release.
  • Vyvanse and generic lisdexamfetamine.
  • Mydayis.
  • Dyanavel XR.
  • Evekeo ODT.

Amphetamine products generally represent the larger commercial stimulant segment. Focalin XR benefits when patients do not respond adequately to amphetamine products or experience adverse effects such as appetite suppression, insomnia, anxiety, or cardiovascular symptoms.

Nonstimulant competitors

Nonstimulant alternatives include Strattera, Qelbree, Intuniv, and generic guanfacine extended release. These products do not provide the same rapid onset as stimulants but have a role for patients with stimulant intolerance, misuse concerns, tics, sleep problems, or inadequate stimulant response.

How strong is the Focalin XR brand and product position?

Focalin XR has a moderate clinical position and a weak economic position.

Factor Assessment Commercial effect
Once-daily dosing Strong Supports adherence and school-day coverage
Dexmethylphenidate mechanism Moderate Differentiates from racemic methylphenidate
Generic availability Weak Limits price and brand retention
Pediatric familiarity Strong Supports continued prescribing
Adult opportunity Moderate Provides volume expansion
Formulation differentiation Moderate Competes with newer delivery systems
Supply reliability Variable Can create temporary switching opportunities
Payer position Weak to moderate Generic products generally receive preferred status

The product’s strongest advantages are physician familiarity, established safety experience, and long-acting dosing. Its main weaknesses are generic substitution, controlled-substance distribution limits, and competition from newer formulations with different onset and duration profiles.

What generic launch risks exist for Focalin XR?

Generic competition creates three principal risks.

First, pharmacy-level substitution diverts prescriptions away from the brand unless a prescriber explicitly requires the branded product. Second, payer formularies generally place generics on lower-cost tiers. Third, multiple manufacturers can compete on contract pricing, creating rapid erosion in average selling price.

The generic market also faces supply constraints. Controlled-substance quota limits, manufacturing interruptions, active pharmaceutical ingredient availability, and DEA distribution requirements can affect product availability. These constraints may temporarily support brand prescriptions, but shortage-driven share gains are difficult to retain after supply normalizes. (U.S. Drug Enforcement Administration, 2024)

What is the FDA and Orange Book status of Focalin XR?

Focalin XR is an FDA-approved prescription controlled substance for ADHD. Its labeling includes boxed warnings concerning abuse, misuse, and addiction risk, along with cardiovascular, psychiatric, growth, and dependence-related warnings. (U.S. Food and Drug Administration, 2024a)

The Orange Book identifies Focalin XR as a reference listed drug for approved generic versions of dexmethylphenidate hydrochloride extended-release capsules. The current commercial issue is therefore substitution and supply, not FDA approval risk for the original product. (U.S. Food and Drug Administration, 2024b)

What patent litigation and settlements affect Focalin XR?

Historical patent disputes involved generic manufacturers seeking approval for dexmethylphenidate extended-release products. Generic applicants typically use Paragraph IV certifications when asserting that listed patents are invalid, unenforceable, or not infringed. The major commercial result of those disputes was eventual generic market access.

There is no widely reported current litigation that materially blocks generic availability or restores Focalin XR exclusivity. Settlement agreements involving generic entry dates can affect historical launch timing, but they do not materially change the present market structure.

What licensing deals support Focalin XR sales?

Focalin XR’s commercial history is primarily associated with Novartis and its U.S. pharmaceutical operations. The product does not have a current licensing structure that creates a significant barrier to generic competition or a major royalty stream visible in public financial reporting.

Authorized-generic or supply arrangements could affect manufacturer economics, but public disclosures do not identify a current deal with enough financial detail to support a separate revenue forecast.

How does Focalin XR compare with Concerta and Vyvanse?

Product Active ingredient Release profile Generic status Relative market position
Focalin XR Dexmethylphenidate Extended release Generic available Mature niche
Concerta Methylphenidate Extended release Generic available Large established segment
Vyvanse Lisdexamfetamine Prodrug, long acting Generic available Major ADHD product
Adderall XR Mixed amphetamine salts Extended release Generic available Large, price-sensitive segment
Azstarys Serdexmethylphenidate/dexmethylphenidate Long acting Brand-led Newer differentiated option

Focalin XR’s competitive value is highest in patients who respond specifically to dexmethylphenidate or who require a methylphenidate-based alternative. It is less attractive as a broad commercial platform because generic versions cover the same active ingredient and dosage form.

What is the investment and commercial outlook for Focalin XR?

Focalin XR is a low-growth, cash-generative mature product category rather than a high-growth branded asset. The primary value lies in:

  • Generic manufacturing and distribution.
  • Supply reliability during stimulant shortages.
  • Contract pricing with pharmacy benefit managers.
  • Portfolio bundling with other ADHD products.
  • Potential international sales in markets where generic penetration remains lower.

The brand has limited standalone licensing value unless a buyer can acquire the product at a low valuation, reduce manufacturing costs, or use it within a broader controlled-substance portfolio.

Key Takeaways

  • Focalin XR is a mature extended-release dexmethylphenidate product for ADHD.
  • Generic competition has removed meaningful U.S. market exclusivity.
  • Estimated U.S. category revenue is approximately $115 million in 2025 and $135 million in 2029 under the base case.
  • Branded Focalin XR revenue is estimated at roughly $15 million to $20 million annually.
  • Generic manufacturers capture most prescription volume and revenue.
  • The main growth drivers are adult ADHD treatment, stimulant shortages, and methylphenidate treatment preference.
  • The main risks are generic price erosion, amphetamine substitution, nonstimulant competition, and controlled-substance supply constraints.
  • The product has moderate clinical durability but weak remaining patent and commercial protection.

FAQs

Is Focalin XR still a profitable brand drug?

Yes, but its profitability is limited by generic competition. The product can generate residual brand revenue, but the higher-value opportunity is usually generic manufacturing or portfolio ownership.

Is dexmethylphenidate extended release interchangeable with Focalin XR?

FDA-approved generics are therapeutically equivalent to the reference product for the approved dosage form, subject to the specific product’s FDA determination and labeling. Pharmacy substitution rules vary by state and payer.

Will Focalin XR sales increase if ADHD diagnoses continue rising?

Higher diagnosis rates can increase total stimulant demand, but they will not necessarily increase branded Focalin XR sales. Generic substitution and competition from Vyvanse, Adderall XR, Concerta, and newer products absorb much of the incremental demand.

Does Focalin XR have biosimilar competition?

No. Focalin XR is a chemically synthesized small-molecule drug, not a biologic. Its competitive threat comes from generic drugs, not biosimilars.

What is the most likely generic launch scenario for Focalin XR?

The most likely scenario is continued multi-manufacturer generic supply, periodic shortages, and gradual price erosion. Temporary brand share gains may occur during generic supply disruptions, but sustained reversion to the brand is unlikely.

References

  1. Centers for Disease Control and Prevention. (2024). Data and statistics on ADHD. https://www.cdc.gov/adhd/data/index.html

  2. U.S. Drug Enforcement Administration. (2024). Established aggregate production quotas for controlled substances. https://www.deadiversion.usdoj.gov

  3. U.S. Food and Drug Administration. (2024a). Focalin XR prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

  4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  5. U.S. Food and Drug Administration. (2024c). Drugs@FDA: Focalin XR, NDA 021278. https://www.accessdata.fda.gov/scripts/cder/daf/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.